XSHE
000766
Market cap2.07bUSD
Oct 09, Last price
14.97CNY
1D
4.25%
1Q
-9.27%
Jan 2017
-14.75%
Name
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. is a Chinese pharmaceutical firm actively involved in the full spectrum of drug development, from research and development to manufacturing and sales. Its therapeutic focus primarily encompasses key areas such as rheumatism, digestive health, oncology, and gynecology. The company boasts a comprehensive and diverse product portfolio. This includes a wide array of traditional Chinese medicines (TCMs), addressing conditions like gynecological issues, rheumatic and bone pain, urological disorders, detoxification needs, cardiovascular and cerebral health, digestive and respiratory ailments, diabetes, and pediatric concerns. Beyond TCMs, it also develops and markets anti-tumor drugs, both prescription and over-the-counter (OTC) medications, and conventional Western pharmaceuticals. These products are available in multiple dosage forms, including capsules, tablets, injections, and liquid preparations. Established in 1990, the company is headquartered in Tonghua, China.
Key people
Yufu Zhang
Chairman of the Board, General Manager · since 2024
Yu Jing
Chief Marketing Officer, Deputy General Manager · since 2020
Xiaolang Yu
Deputy General Manager · since 2015
Hailong Zhang
Executive Deputy General Manager · since 2023
Weilin Jia
Secretary of the Board · since 2023
Huan Wang
Deputy General Manager, Director · since 2023
Yingjie Wei
Director · since 2020
Chief Financial Officer, Deputy General Manager, Director · since 2023
Haoyan Zhang
General Manager, Director · since 2023
Qiang Zhou
Director · since 2020
Independent Director · since 2020
Ling Zhang
Independent Director · since 2024
Wei Zhao
Independent Director · since 2025
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||